Rick Gonzalez, AbbVie CEO (AP Images)
AbbVie makes a hefty play to boost aesthetics business, paying $550M for non-invasive body sculpting device
When AbbVie chose to prop up its Allergan Aesthetics unit as a separate business post-merger, it set off some alarm bells that a spinoff or …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
